Page 121 - 《中国药房》2023年22期

critically ill neonates：a case-control study[J]. Pediatr Neo‐ safety profile comparison of colistin and tigecycline on
natol，2017，58（6）：490-496. the extensively drug resistant Acinetobacter baumannii[J].
[22] BETROSIAN A P，FRANTZESKAKI F，XANTHAKI A， Biol Pharm Bull，2014，37（3）：340-346.
et al. Efficacy and safety of high-dose ampicillin/sulbac‐ [33] LIM S K，LEE S O，CHOI S H，et al. The outcomes of
tam vs. colistin as monotherapy for the treatment of multi‐ using colistin for treating multidrug resistant Acinetobacter
drug resistant Acinetobacter baumannii ventilator-associated species bloodstream infections[J]. J Korean Med Sci，
pneumonia[J]. J Infect，2008，56（6）：432-436. 2011，26（3）：325-331.
[23] CHUANG Y C，CHENG C Y，SHENG W H，et al. Effec‐ [34] PAUL M，BISHARA J，LEVCOVICH A，et al. Effective‐
tiveness of tigecycline-based versus colistin- based therapy ness and safety of colistin：prospective comparative cohort
for treatment of pneumonia caused by multidrug-resistant study[J]. J Antimicrob Chemother，2010，65（5）：1019-1027.
Acinetobacter baumannii in a critical setting：a matched [35] REINA R，ESTENSSORO E，SÁENZ G，et al. Safety and
cohort analysis[J]. BMC Infect Dis，2014，14：102. efficacy of colistin in Acinetobacter and Pseudomonas
[24] DURAKOVIC N，RADOJCIC V，BOBAN，et al. Efficacy infections：a prospective cohort study[J]. Intensive Care
and safety of colistin in the treatment of infections caused Med，2005，31（8）：1058-1065.
by multidrug-resistant Pseudomonas aeruginosa in patients [36] RIOS F G，LUNA C M，MASKIN B，et al. Ventilator-
with hematologic malignancy：a matched pair analysis[J]. associated pneumonia due to colistin susceptible-only
Intern Med，2011，50（9）：1009-1013. microorganisms[J]. Eur Respir J，2007，30（2）：307-313.
[25] GARNACHO-MONTERO J，ORTIZ-LEYBA C，JIMÉNEZ- [37] SHIELDS R K，NGUYEN M H，CHEN L，et al.
JIMÉNEZ F J，et al. Treatment of multidrug-resistant Ceftazidime-avibactam is superior to other treatment regi‐
mens against carbapenem-resistant Klebsiella pneumoniae
Acinetobacter baumannii ventilator-associated pneumonia
（VAP） with intravenous colistin：a comparison with bacteremia[J]. Antimicrob Agents Chemother，2017，61
imipenem-susceptible VAP[J]. Clin Infect Dis，2003，36 （8）：e00883-e00817.
（9）：1111-1118. [38] AGGARWAL R，DEWAN. Comparison of nephrotoxicity
of colistin with polymyxin B administered in currently
[26] GOUNDEN R，BAMFORD C，VAN ZYL-SMIT R，et al.
Safety and effectiveness of colistin compared with tobra‐ recommended doses：a prospective study[J]. Ann Clin
mycin for multi-drug resistant Acinetobacter baumannii Microbiol Antimicrob，2018，17（1）：15.
[39] CRASS R L，RUTTER W C，BURGESS D R，et al. Nephro-
infections[J]. BMC Infect Dis，2009，9：26.
[27] HACHEM R Y，CHEMALY R F，AHMAR C A，et al. toxicity in patients with or without cystic fibrosis treated
Colistin is effective in treatment of infections caused by with polymyxin B compared to colistin[J]. Antimicrob
Agents Chemother，2017，61（4）：e02329-e02316.
multidrug-resistant Pseudomonas aeruginosa in cancer
patients[J]. Antimicrob Agents Chemother，2007，51（6）： [40] RIGATTO M H，OLIVEIRA M S，PERDIGÃO-NETO L
1905-1911. V，et al. Multicenter prospective cohort study of renal fai-
lure in patients treated with colistin versus polymyxin B[J].
[28] KALLEL H，HERGAFI L，BAHLOUL M，et al. Safety Antimicrob Agents Chemother，2016，60（4）：2443-2449.
and efficacy of colistin compared with imipenem in the [41] PHE K，LEE Y M，MCDANELD P M，et al. In vitro
treatment of ventilator-associated pneumonia：a matched
assessment and multicenter cohort study of comparative
case-control study[J]. Intensive Care Med，2007，33（7）：
nephrotoxicity rates associated with colistimethate versus
1162-1167. polymyxin B therapy[J]. Antimicrob Agents Chemother，
[29] KARABAY O，BATIREL A，BALKAN I，et al. Efficacy 2014，58（5）：2740-2746.
of colistin and non-colistin monotherapies in multi-drug
[42] TUON F F，RIGATTO M H，LOPES C K，et al. Risk fac‐
resistant Acinetobacter baumannii bacteremia/sepsis[J]. tors for acute kidney injury in patients treated with poly‐
Acta Medica Mediterranea，2014，30：1137-1143. myxin B or colistin methanesulfonate sodium[J]. Int J
[30] KIM W Y，MOON J Y，HUH J W，et al. Comparable effi‐
Antimicrob Agents，2014，43（4）：349-352.
cacy of tigecycline versus colistin therapy for multidrug- [43] AKAJAGBOR D S，WILSON S L，SHERE-WOLFE K
resistant and extensively drug-resistant Acinetobacter bau‐ D，et al. Higher incidence of acute kidney injury with
mannii pneumonia in critically ill patients[J]. PLoS One， intravenous colistimethate sodium compared with poly‐
2016，11（3）：e0150642. myxin B in critically ill patients at a tertiary care medical
[31] KOOMANACHAI P，TIENGRIM S，KIRATISIN P，et al. center[J]. Clin Infect Dis，2013，57（9）：1300-1303.
Efficacy and safety of colistin（colistimethate sodium）for [44] MANCHANDANI P，ZHOU J，BABIC J T，et al. Role of
therapy of infections caused by multidrug-resistant Pseu‐ renal drug exposure in polymyxin B-induced nephrotoxi-
domonas aeruginosa and Acinetobacter baumannii in Siri‐ city[J]. Antimicrob Agents Chemother，2017，61（4）：
raj Hospital，Bangkok，Thailand[J]. Int J Infect Dis，2007， e02391-e02316.
11（5）：402-406. （收稿日期：2023-04-27 修回日期：2023-10-25）
[32] KWON S H，AHN H L，HAN O Y，et al. Efficacy and （编辑：陈 宏）

中国药房 2023年第34卷第22期 China Pharmacy 2023 Vol. 34 No. 22 · 2799 ·